Business Context and Reporting Period
Seastar Medical Holding Corp (ICU) filed a Form 8-K on September 26, 2023, reporting the completion of the third Additional Closing under a Securities Purchase Agreement (SPA) with an institutional investor. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial results. Key metrics from this event include:
- Principal Amount Raised: $543,478.26 via a convertible promissory note.
- Warrants Issued: Rights to purchase up to 738,791 shares of Common Stock.
- Conversion Price: Set at the lowest of $0.20, the closing sale price on the trading day preceding conversion, or the average closing sale price for the five consecutive trading days preceding conversion.
- Total SPA Capacity: The investor may purchase up to $2 million in aggregate principal amount of Notes.
Material Changes
The filing details the execution of a tranche of debt financing previously authorized. No comparative financial period data (e.g., revenue or profit changes) is provided in this specific report.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the terms of the financing. The transaction involves convertible debt with a variable conversion price mechanism, which may result in significant dilution to existing shareholders depending on the stock price at the time of conversion.
Investor Verification Checklist
- Verify the current trading price of ICU stock to assess the potential dilution impact of the $0.20 conversion price floor.
- Review the original March 16, 2023, Form 8-K for full terms of the SPA, including interest rates and maturity dates of the Notes.
- Confirm the remaining capacity available under the $2 million SPA agreement.
- Check subsequent filings for the actual conversion of these notes into equity.